Rob Hershberg, HilleVax CEO
September 8, 2021 08:00 AM EDTUpdated 08:59 AM
Financing

One of Tachi's new­ly born lega­cy biotechs rais­es $135M and en­lists an A-list board to ad­vance late-stage vac­cine

Paul Schloesser

Associate Editor

Tachi is gone, but his lega­cy biotechs are con­tin­u­ing to make news.

This morn­ing it’s the new­ly born Hill­e­Vax — a cre­ation of Take­da and Fra­zier …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times